The Promise of Adjuvant Immunotherapy in Renal-Cell Carcinoma
Mené sur 496 patients atteints d'un carcinome à cellules rénales, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans maladie, et la toxicité du pembrolizumab après une néphrectomie
Renal-cell carcinoma is a common cancer in both men and women around the world. Although nephrectomy remains the standard care for patients with locally advanced renal-cell carcinoma, recurrence occurs in up to 50 to 80% of patients, ultimately causing death from the disease. Adjuvant therapy, conceptually developed in the 1960s, is used to improve cure rates and prolong survival after surgical resection. The first studies of adjuvant therapy in renal-cell carcinoma began in the 1980s,1 and since that time, multiple trials have been conducted to test chemotherapy, immunotherapy, and targeted therapy regimens in patients after nephrectomy. Despite numerous worthy attempts,